At the news
? NEUTRALIMPACT 6/10 DEFA14A filed Nov 9, 2026 at 07:53 ET
CorMedix entered into a loan agreement with BioPharma Credit for up to $50M in Tranche B term loans, and simultaneously signed an asset purchase agreement with Heron Therapeutics to acquire multiple commercial-stage products (Cinvanti, Zynrelef, Aponvie, Sustol) for $145M in cash plus 14,583,333 shares of CorMedix common stock. The loan proceeds are designated to fund the Heron acquisition and potential other acquisitions.
- CorMedix entered a loan agreement with BioPharma Credit for up to $50M in Tranche B term loans dated November 8, 2026.
- CorMedix signed an asset purchase agreement with Heron Therapeutics to acquire Cinvanti, Zynrelef, Aponvie, and Sustol.
- Total cash consideration for the Heron acquisition is $145M plus 14,583,333 shares of CorMedix common stock.
- The loan proceeds are to fund the Heron Acquisition Transaction and potential other acquisitions.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access